Diagnostic criteria for multiple sclerosis (MS) have undergone numerous revisions, the latest announced in 2024.
Objectives:
This study compared the 2024 McDonald criteria with earlier iterations regarding sensitivity, time to MS diagnosis, and disability. Patients with clinically or radiologically isolated syndrome (CIS, RIS) between 2013 and 2022, aged 18–50, visited within 6 months, and with brain MRI were included. The primary outcome was MS diagnosis according to 2024 versus 2017 criteria. Secondary outcomes included time to diagnosis and disability by Multiple Sclerosis Severity Score. Outcomes were stratified into pre-2017 and 2017–2022 cohorts, with 2010 criteria applied to the pre-2017 group. Finally, 2024 criteria were prospectively tested.
Results:
Among 163 patients (mean age 31.4; 72% female), for the 2024 criteria, diagnosis sensitivity was 81.4% versus 74.9% for 2017 criteria; in the pre-2017 cohort, 49.4% for 2010 criteria. Median time to diagnosis was shorter with 2024 criteria (2.0 [IQR 1.1–4.2] months) compared to 2017 and 2010 criteria (2.1 [1.2–4.7] and 3.8 [1.5–11.2], respectively). Patients fulfilling 2024 and 2017 criteria at baseline showed lower MSSS during follow-up than those meeting 2010 criteria. Prospectively, 11/13 (85%) fulfilled 2024 criteria at baseline.
Conclusions:
The 2024 McDonald criteria increased sensitivity, shortened time to diagnosis, and identified patients with milder disease course.
PoserCMPatyDWScheinbergL, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol1983; 13(3): 227–231.
2.
TintoreMRoviraÀRíoJ, et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain2015; 138(Pt. 7): 1863–1874.
3.
YamoutBSahraianMBohlegaS, et al. Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines. Mult Scler Relat Disord2020; 37: 101459.
4.
ComiGMartinelliVRodegherM, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): A randomised, double-blind, placebo-controlled trial. Lancet2009; 374: 1503–1511.
5.
KapposLEdanGFreedmanMS, et al. The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology2016; 87: 978–987.
6.
MillerAEVermerschPKapposL, et al. Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study. Mult Scler Relat Disord2019; 33: 131–138.
7.
LeistTPComiGCreeBA, et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): A phase 3 randomised trial. Lancet Neurol2014; 13(3): 257–267.
8.
PalaceJDuddyMLawtonM, et al. Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: Final 10-year results from the UK multiple sclerosis risk-sharing scheme. J Neurol Neurosurg Psychiatry2019; 90(3): 251–260.
9.
BrownJWLColesAHorakovaD, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA2019; 321: 175–187.
10.
HeAMerkelBBrownJWL, et al. Timing of high-efficacy therapy for multiple sclerosis: A retrospective observational cohort study. Lancet Neurol2020; 19(4): 307–316.
11.
McDonaldWICompstonAEdanG, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol2001; 50(1): 121–127.
12.
PolmanCHReingoldSCEdanG, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol2005; 58(6): 840–846.
13.
PolmanCHReingoldSCBanwellB, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol2011; 69(2): 292–302.
14.
ThompsonAJBanwellBLBarkhofF, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol2018; 17: 162–173.
15.
MontalbanXLebrun-FrenayCOhJ, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald Criteria. Lancet Neurol2025; 24: 850–865.
16.
BarkhofFReichDSOhJ, et al. 2024 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosis. Lancet Neurol2024; 24: 866–879.
17.
SaidhaSGreenAJLeocaniL, et al. The use of optical coherence tomography and visual evoked potentials in the 2024 McDonald diagnostic criteria for multiple sclerosis. Lancet Neurol2024; 24: 880–892.
18.
Lebrun-FrenayCOkudaDTSivaA, et al. The radiologically isolated síndrome: Revised diagnostic criteria. Brain2023; 146: 3431–3443.
19.
SatiPOhJConstableRT, et al. The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: A consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nat Rev Neurol2016; 12(12): 714–722.
20.
GillAJSchorrEMGadaniSP, et al. Emerging imaging and liquid biomarkers in multiple sclerosis. Eur J Immunol2023; 53(8): e2250228.
21.
RoxburghRHSSeamanSRMastermanT, et al. Multiple sclerosis severity score: Using disability and disease duration to rate disease severity. Neurology2005; 64: 1144–1151.
22.
van der Vuurst de VriesRMMescheriakovaJYWongYYM, et al. Application of the 2017 revised McDonald criteria for multiple sclerosis to patients with a typical clinically isolated syndrome. JAMA Neurol2018; 75: 1392–1398.
23.
TintoreMCobo-CalvoACarbonellP, et al. Effect of changes in MS diagnostic criteria over 25 years on time to treatment and prognosis in patients with clinically isolated syndrome. Neurology2021; 97: e1641–e1652.
24.
FilippiMPreziosaPMeaniA, et al. Performance of the 2017 and 2010 revised McDonald criteria in predicting MS diagnosis after a clinically isolated syndrome: A MAGNIMS study. Neurology2022; 98: e1–e14.
25.
FerrandMEpsteinJSoudantM, et al. Real-life evaluation of the 2017 McDonald criteria for relapsing-remitting multiple sclerosis after a clinically isolated syndrome confirms a gain in time-to-diagnosis. J Neurol2024; 271(1): 125–133.
26.
McNicholasNLockhartAYapSM, et al. New versus old: implications of evolving diagnostic criteria for relapsing-remitting multiple sclerosis. Mult Scler2019; 25(6): 867–870.
27.
HardingKWilliamsOWillisM, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol2019; 76: 536–541.
28.
SharminSRoosIMalpasC, et al. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: A longitudinal analysis of a global and national registry. Lancet Child Adolesc Health2024; 8: 348–357.
29.
Cobo-CalvoATurCOtero-RomeroS, et al. Association of very early treatment initiation with the risk of long-term disability in patients with a first demyelinating event. Neurology2023; 101: e1280–e1292.
30.
OkudaDTKantarciOLebrun-FrénayC, et al. Dimethyl fumarate delays multiple sclerosis in radiologically isolated syndrome. Ann Neurol2023; 93(3): 604–614.
31.
Lebrun-FrénayCSivaASormaniMP, et al. Teriflunomide and time to clinical multiple sclerosis in patients with radiologically isolated syndrome: The TERIS randomized clinical trial. JAMA Neurol2023; 80: 1080–1088.
